JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes

C-peptide, a biomarker that indicates insulin production, is a validated surrogate endpoint in type 1 diabetes clinical trials NEW YORK, May 20, 2024 /PRNewswire/ — A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the…